Partial filing excerpt: Part I table of contents plus selected 2025/2024 financial statements (total assets $100,942,881 in 2025; net loss $24,761,369 in 2025), with no business description, customer counts, employee counts, or revenue figures disclosed.

# Summary (based only on the provided text)

- The provided excerpt is a table-of-contents fragment for "PART I" of a filing. It lists the following Item headings and corresponding page numbers:
  - Item 1. Business — page 1
  - Item 1A. Risk Factors — page 18
  - Item 1B. Unresolved Staff Comments — page 47
  - Item 1C. Cybersecurity — page 47
  - Item 2. Properties — page 48
  - Item 3. Legal Proceedings — page 48
  - Item 4. Mine Safety Disclosures — page 48

- No substantive description of the company’s business operations is included in the excerpt. The excerpt does not contain any information about:
  - what the company actually does (products/services, markets, business model),
  - number of customers,
  - number of employees,
  - revenue or income figures,
  - or any other quantitative operational or financial details.

If you provide the text from Item 1 (Business) or other substantive sections, I can produce a detailed, specific summary including counts and financial figures that appear in those sections.

The Company is a Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands, focusing on acquiring target businesses primarily in Asia with strategic growth potential.

# The Company

## Overview
The Company is a publicly listed Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands on March 1, 2021. Its purpose is to pursue business combinations (mergers, acquisitions, or similar transactions) with one or more target businesses primarily in Asia, excluding the PRC, Hong Kong, and Macau.

## Operations
- Current status: SPAC focused on identifying and evaluating acquisition candidates.
- Revenue: None to date.
- Losses: The Company has recorded losses since inception related to formation and operating costs.

## Financial activity
- Initial Public Offering (IPO)
  - Date: October 18, 2022
  - Units issued: 6,600,000 units
  - Gross proceeds: $66,000,000
  - Unit composition: one ordinary share and one right to receive two-tenths (0.2) of one ordinary share
- Private placement
  - Date: Concurrent with the IPO
  - Units issued: 394,000 units at $10.00 each
  - Proceeds: $3,940,000
- Trust account: $67,320,000 of net proceeds from the IPO and private placement are held for the benefit of public shareholders in a U.S.-based trust account.

## Management and staffing
- Officers: 2 officers; no full-time employees prior to completing an initial business combination.
- Management
  - Mr. Xiaofeng Yuan — Chief Executive Officer, Executive Director, and Chairman; experience in the healthcare industry in China.
  - Mr. Taylor Zhang — Chief Financial Officer; background in financial services and capital markets.

## Competitive position
- Management experience in mergers and acquisitions, finance, and operations supports the Company's ability to source and execute business combinations.
- As a publicly listed vehicle, the Company offers target businesses a pathway to U.S. capital markets that may be more efficient than a traditional IPO.

## Acquisition strategy
- Target geography: Private companies in Asia (excluding PRC, Hong Kong, Macau).
- Target criteria: Businesses with compelling economics, experienced management teams, and strong potential for revenue and earnings growth.
- Target enterprise value: $200 million to $600 million.

## Compliance and risks
- The Company operates without a direct presence in China and intends to target businesses that comply with U.S. laws. Directors and officers with ties to China may expose the Company to PRC regulatory oversight.
- Auditor: Marcum LLP, which is subject to PCAOB inspection as part of compliance with U.S. securities laws.

CITIUS ONCOLOGY, INC.

10-K / December 23, 2025

10-K / April 16, 2024

10-K / December 23, 2025

Summary (based only on the provided text)